Insights
Search Results
Client Highlights
7.01.26
Wilson Sonsini Advises Kai Health on $4.8 Million Seed Round
On June 29, 2026, Kai Health, an AI-powered performance improvement platform for emergency medicine, announced a $4.8 million seed round led by Distributed Ventures. Wilson Sonsini Goodrich & Rosati advised Kai Health on the transaction.
Client Highlights
7.01.26
Wilson Sonsini Advises yes& on $3 Million Pre-Seed Financing
On June 23, 2026, yes&, a remix-native AI creative community platform, announced that it has raised $3 million in pre-seed funding, led by Accel with support from Parable. Wilson Sonsini Goodrich & Rosati advised yes& on the transaction.
Client Highlights
6.30.26
Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric
On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.
Client Highlights
6.30.26
Wilson Sonsini Advises Rocket Lab on $8 Billion Acquisition of Iridium
On June 29, 2026, Rocket Lab Corporation, a global leader in launch and space systems, and Iridium Communications, a leading provider of global voice, data and positioning, navigation, and timing satellite services, announced they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8 billion. Wilson Sonsini Goodrich & Rosati is advising Rocket Lab on the transaction.
Client Highlights
6.25.26
Wilson Sonsini Advises Sail Research on $80 Million Series A
On June 25, 2026, Sail Research, an infrastructure company purpose-built for long-horizon AI agents, announced it has raised $80 million in seed and Series A funding at a $450 million valuation. The Series A was led by Kleiner Perkins, and the seed round was led by Sequoia. Other participating investors included Redpoint Ventures, Theory Ventures, Vine Ventures, CRV, A*, and Abstract Ventures, in addition to angel investors, including John Hennessy, chairman of Alphabet Inc., Lip-Bu Tan, CEO of Intel, and Tri Dao, Chief Scientist at Together AI. Wilson Sonsini Goodrich & Rosati advised Sail Research on the transaction.
Client Highlights
6.24.26
Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Client Highlights
6.24.26
Wilson Sonsini Advises Assort Health on $120 Million Series C
On June 24, 2026, Assort Health, the most widely used AI agents platform for the patient journey, announced a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion. Assort has now raised more than $222 million to become the standard for healthcare organizations wanting to transform the patient journey with AI. Wilson Sonsini Goodrich & Rosati advised Assort on the transaction.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
Client Highlights
6.24.26
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
Client Highlights
6.23.26
Firm Advises QCi on Acquisition of NHanced
On June 22, 2026, Quantum Computing Inc. (QCi), an innovative, quantum optics and integrated photonics technology company, announced the completion of acquiring NHanced Semiconductors for a combination of cash and QCi stock valued at $73.1 million, subject to customary adjustments, and up to an additional $72.0 million if certain performance targets are achieved. Wilson Sonsini Goodrich & Rosati advised QCi on the transaction.
Client Highlights
6.22.26
Firm Advises Denali Therapeutics on Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
On June 18, 2026, Denali Therapeutics, a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform, announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. Wilson Sonsini Goodrich & Rosati advised Denali on the transaction.
Client Highlights
6.18.26
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.